Interferon “Signatures” Improve Diagnostic Capabilities of Biomarkers and Indicate Most-Appropriate, Personalized Courses of Treatment
This diagnostic microarray accurately identifies specific diseases and subsequent treatment options using interferon-responsive genes. Most diseases, either infectious or autoimmune, trigger an immune response in humans and animals with an intact immune system. In response, host cells of the immune system produce interferon, a large group of signaling proteins that interferes with microbial replication and cellular inflammation. Available biomarkers for disease identification are often indirect or non-specific markers of the pathological state, which can hinder or incorrectly identify unrelated diseases. Researchers at the University of Florida developed a diagnostic microarray that targets interferon-responsive gene sets induced during immune responses, improving the diagnostic capability of biomarkers. The diagnostic microarray uses interferon-responsive genes to develop interferon signatures indicative of specific disease states or treatments.
Microarrays for more accurate identification of specific diseases and treatments
- Identifies diseases using interferon-responsive gene sets and signatures, improving the accuracy and specificity of diagnoses and treatments
- Uses differential gene set expressions as biomarkers, extending the diagnostic capabilities
When specific combinations of interferon-responsive genes are activated by the immune system, they serve as an interferon “signature,” which uniquely identifies a response caused by a specific disease or pathogen. These interferon signature can then be used to identify biomarkers for a more accurate and specific indication of disease states and treatments. University of Florida researchers developed a diagnostic microarray that uses these interferon-responsive gene sets and signatures to determine disease states and treatments. The diagnostic microarray uses a substrate containing multiple attached oligonucleotides at predetermined locations on its surface. Each specific location contains at least one material targeting an interferon-responsive gene, and can target up to 1500 different interferon-responsive genes. The attached oligonucleotides attract interferon-responsive genes and gene products via covalent bond. Additionally, a database of known interferon signatures can be logged in specialized computer systems to collect data and diagnose diseases, providing more effective treatment recommendations for patients.